Neratinib-based combination therapy in HER2-Mutant lung cancer

Treatment Updated for HER2 Positive Breast Cancer: Changing ParadigmsПодробнее

Neratinib Plus Fulvestrant for HER2 Mutant, Non-Amplified Metastatic Breast CancerПодробнее

Neratinib in HER2 or HER3 mutant solid tumoursПодробнее

Sramila Aithal, MD | Neratinib and Dose Escalation | Optimizing Therapy for HER2+ DiseaseПодробнее

GS4 10 Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastaticПодробнее

Dr. Yorio on T-DM1 in HER2-Mutant Lung Cancer TreatmentПодробнее

Neratinib, trastuzumab + fulvestrant for HER2-mutant, HR+, metastatic breast cancerПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Hope S. RugoПодробнее

Neratinib + fulvestrant + trastuzumab for HR+ HER2-mutant mBC and neratinib + trastuzumab for tr...Подробнее

Treating HER2 Exon-20 Insertion NSCLC with Trastuzumab Deruxtecan - Case Based Panel DiscussionПодробнее

What is a HER2 mutation in lung cancer?Подробнее

HER2 Mutation Positive NSCLCПодробнее

Dr Davis on the Investigation of Neratinib + Trastuzumab Deruxtecan in Advanced HER2+ Solid TumorsПодробнее

Case Based Panel Discussion NSCLC – Does a Positive HER2 Mutation Effect Treatment Decisions?Подробнее

Treating HER2-mutant advanced biliary tract cancer with neratinibПодробнее

Neratinib + Capecitabine in HER2+ Breast CancerПодробнее

Neratinib for Metastatic Breast CancerПодробнее

Study of Neratinib for Patients with HER2-Positive Breast Cancer with Brain MetastasesПодробнее

Neratinib in MBC with HER2 Activating MutationsПодробнее